|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||12.98 - 13.22|
|52-week range||12.98 - 13.22|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The call will also be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, president and chief executive officer; and Sandra Boenisch, principal financial officer.
Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...